J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
United Airlines Cuts Flights 5% Amid Soaring Fuel Costs From Iran War 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Iran-U.S. War Sends Dollar Higher as Middle East Tensions Escalate 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Goldman Sachs Raises Oil Price Forecasts Amid Strait of Hormuz Disruptions 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Global Markets Reel as Middle East Tensions Escalate Energy Fears 
Oil Prices Hold Steady Amid Middle East Escalation and Sanctions Relief 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
